CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
anti-CCR2 monoclonal antibody MLN1202 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01015560
NCT01015560Phase 2Completed
CompareCT.gov

S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases

SWOG Cancer Research Network·interventional·Posted Nov 18, 2009·Updated Aug 9, 2018

In Brief

A Phase 2 clinical trial evaluating anti-CCR2 monoclonal antibody MLN1202, polymorphism analysis, and 1 other intervention for Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 44 participants across 47 sites.

Detailed Summary

RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works in treating patients with bone metastases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2009
Enrollment StartMar 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.6 years ago

Interventions

anti-CCR2 monoclonal antibody MLN1202drug

polymorphism analysisgenetic

laboratory biomarker analysisother